L1: (Endometriosis & Adenomyosis)(4mcq) L2: (Disorders of Early Pregnancy I)(part I&II 8mcq) L3: (Recurrent Miscarriage II)(part I&II 8mcq) L4: (Ectopic Pregnancy)(4mcq) L5: (Gestational Trophoblastic Diseases)(3mcq) L6: (Benign Diseases of the Uterus)(4mcq) L7: (Endometrial Hyperplasia -pre-)(premalignant&malignant 2mcq) L8: (Malignant Uterine Disease)(premalignant&malignant 2mcq) L9: (Minimal Access Surgery)(2mcq) L10: (Ovarian Disease Part 1)(part I&II 5mcq) L11: (Ovarian Diseases Part 2)(part I&II 5mcq) 📊 Ultimate Comparisons (10 Tables)

Ultimate Exam Guide

L1: (Endometriosis & Adenomyosis)(4mcq)

Endometriosis: Definition & Pathogenesis
  • Definition: Inflammatory disease characterized by lesions of endometrial-like tissue (glands & stroma) outside the uterus.
  • Locations: Usually within the pelvis, but very rarely at distant sites (lung, vagina, bowel, bladder, or ureter). Anterior abdominal wall endometrioma may develop in abdominal scars (Caesarean section) or umbilicus after laparoscopy.
  • It is an Oestrogen-dependent disease with growing evidence of progesterone resistance. Resolves after menopause or via pseudomenopause state.
  • Pathogenesis Theories:
    1. Retrograde Menstruation (Sampson's Theory): Occurs in 90% of women, but only a minority develop disease. Explains why it occurs with vaginal outflow obstruction and higher risk in short menstrual cycles, increased duration of bleeding, and decreased parity.
    2. Coelomic Epithelium Transformation: Mullerian duct, peritoneal cells, and ovarian cells share a common origin and transform due to hormonal stimuli.
    3. Genetic & Immunological Factors: Increased incidence in first-degree relatives (6-9 times more). Immunologic surveillance defect (altered systemic humoral immunity, altered B-cell function) causes failure to clear cells.
    4. Vascular & Lymphatic Spread: Explains rare distant sites (kidney, lungs, joints, skin).
  • Protective Factors: Smoking, exercises, and Combined Oral Contraceptive Pills (COCP) use may protect and decrease incidence.
Endometriosis: Phenotypes, Symptoms & Diagnosis
  • Phenotypes at Laparoscopy:
    1. Superficial (Typical): Powder burn, gunshot, or burned match stick appearance. Highly responsive to oestrogen (free implants).
    2. Deep Endometriosis: Lesions extending deeper than 5 mm under the peritoneal surface (enclosed implants). Partial response to hormonal treatment.
    3. Healed Lesions: Surrounded by connective scar tissue; insensitive to hormonal stimuli.
    4. Endometrioma (Chocolate Cyst): Cystic ovarian endometriosis containing dark brown fluid. Multiple implants inevitably interfere with fertility.
  • Clinical Presentation: Highly variable. No relation between the extent of disease and severity of symptoms.
    • Reproductive Tract: Secondary dysmenorrhoea (starts days before menses), deep dyspareunia, chronic pelvic pain, subfertility (30-40%).
    • Gastrointestinal Tract (GIT): Dyschezia (painful defecation), cyclical rectal bleeding. Dyspareunia and dyschezia are key indicators of pouch of Douglas (rectovaginal) endometriosis.
    • Urinary: Cyclical haematuria.
    • Lung: Cyclical haemoptysis and haemopneumothorax.
    • Highly suggestive symptom: Severe dysmenorrhoea unresponsive to usual analgesics.
  • Vaginal Examination Signs: Thickening/nodules at uterosacral ligament, tenderness at Pouch of Douglas, fixed retroverted uterus, ovarian mass.
  • Diagnosis:
    • Laparoscopy: The Gold Standard. Diagnostic & therapeutic. Adhesions are strongly suggestive. Biopsy required for endometriomas >3 cm.
    • Ultrasound: Identifies endometriomas (Kissing ovaries). Negative ultrasound does NOT exclude the disease (no value for peritoneal lesions).
    • Magnetic Resonance Imaging (MRI): Not superior to ultrasound for endometrioma, but helps evaluate deep lesions.
    • Cancer Antigen 125 (CA-125): Increases in severe endometriosis, but not of diagnostic value alone.
Endometriosis: Classification & Treatment
  • r-ASRM Classification (Revised American Society for Reproductive Medicine): Based on size, site, adhesions, and obliteration of pouch of Douglas.
    • Stage 1 (Minimal, Score 1-5): Isolated implant, no adhesions.
    • Stage 2 (Mild, Score 6-15): Superficial implants scattered, no significant adhesions.
    • Stage 3 (Moderate, Score 16-40): Multiple superficial/deep implants. Adhesions on tubes/ovaries.
    • Stage 4 (Severe, Score >40): Deep implants, large endometriomas, dense adhesions.
  • Medical Treatment: Acts by ovarian suppression. Does not remove local disease (symptoms recur after stoppage). No effect on endometrioma/adhesions. No evidence of fertility benefit.
    • Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): For pain.
    • Combined Oral Contraceptive Pills (COCP): Continuous use (pseudopregnancy state).
    • Progesterone: High dose oral (100mg/day) or depot medroxyprogesterone acetate (150mg/3 months). Causes endometrial atrophy.
    • Danazol/Gestrinone: Androgenic effects. 400-600mg/day. Side effects: weight gain, acne, voice deepening.
    • Gonadotropin-Releasing Hormone (GnRH) agonists: Induces pseudomenopause state. Side effects: osteoporosis (requires add-back low dose HRT if used >6 months).
  • Surgical Treatment:
    • Conservative (Fertility-sparing): Laparoscopic diathermy/laser. Best for endometrioma (simple drainage has rapid recurrence, excision is choice). Pre-sacral neurectomy for chronic pain.
    • Definitive: Hysterectomy & bilateral salpingo-oophorectomy. HRT given 6 months after surgery to decrease recurrence risk.
Adenomyosis
  • Definition: Presence of endometrial glands & stroma in the myometrium with adjacent smooth muscle hyperplasia.
  • Epidemiology: Unlike endometriosis, it is more common in parous, middle-aged women (late 30s-early 40s).
  • Symptoms: Heavy painful menstruation (menorrhagia & secondary dysmenorrhea). Uterus may be bulky & tender.
  • Diagnosis: Magnetic Resonance Imaging (MRI) is the investigation of choice. Transvaginal ultrasound may show myometrial cysts, asymmetric myometrial thickening, subendometrial linear striation.
  • Treatment:
    • Medical: NSAIDs, COCP, LNG-IUS (Mirena) preferred over endometrial ablation.
    • Surgical: Hysterectomy is definitive. Endometrial ablation has high failure rate due to deep lesions regenerating.
💡 High-Yield Hints (L1)
  • Pouch of Douglas Involvement: Suspect if patient has dyspareunia AND dyschezia.
  • Gold Standard Diagnosis for Endometriosis: Laparoscopy. Ultrasound alone CANNOT exclude peritoneal lesions.
  • Endometrioma Management: Simple drainage causes rapid recurrence; laparoscopic excision is the treatment of choice.
  • Adenomyosis vs Endometriosis: Adenomyosis typically affects older (late 30s/40s) PAROUS women. Endometriosis often starts in teenagers/nulliparous.
  • GnRH Agonist Limitation: Causes osteoporosis if used >6 months. Requires "add-back" HRT.
  • Definitive Surgery Rule: Hysterectomy + BSO for endometriosis requires delaying HRT for 6 months post-op to prevent recurrence.

L2: (Disorders of Early Pregnancy I)(part I&II 8mcq)

Early Pregnancy Diagnosis & General Info
  • Symptom Triad: Amenorrhea, Lower abdominal pain, Vaginal bleeding.
  • Diagnosis:
    • Plasma Human Chorionic Gonadotropin (hCG): Detects pregnancy 6-7 days post-ovulation (limit 0.1-0.3 IU/L). Normal pregnancy: hCG doubles every 48 hours (rises by >65%).
    • Transvaginal Ultrasound (TVUS): Gestational sac seen at 4.3-4.6 weeks (2-4mm). Abdominal US at 5 weeks. Fetal heart activity at 6-7 weeks.
    • Discriminatory Zone: Intrauterine pregnancy should be seen on TVUS when hCG is >1500 IU/L.
    • Yolk Sac: Visible when sac is 8 mm. Confirms true sac (excludes ectopic pseudosac).
    • Pregnancy of Unknown Location (PUL): Positive hCG but location unidentifiable on TVUS.
Miscarriage (Abortion): Definitions, Causes & Types
  • Definition: Spontaneous end before 24 weeks (viability). WHO: before 20 weeks or fetus <500g. Highest incidence at 5-6 weeks (25%). >80% occur in first 12 weeks.
  • Risk Factors: Advanced maternal age (most important - risk doubles at 40y), smoking/cocaine, Intrauterine Contraceptive Device (IUCD) in situ, previous miscarriages (risk increases to 25-30% after 3 aborts). COCP does NOT increase risk.
  • Aetiology:
    • Chromosomal abnormalities (50-60%): Most common is autosomal trisomy, then triploidy, monosomy. Blighted ovum (empty sac >25mm).
    • Endocrine: Diabetes, Hypothyroidism, Polycystic Ovary Syndrome (PCOS), Luteal phase deficiency (insufficient progesterone before 8 weeks).
    • Uterine: Septate/bicornuate uterus, Asherman's syndrome, submucosal fibroids, cervical incompetence (causes 2nd-trimester loss).
    • Infections: Uncommon. Toxoplasmosis, CMV, Listeriosis, Rubella, Chlamydia.
  • Clinical Varieties:
    • Threatened: Mild bleeding, no/mild pain. Cervix CLOSED. US shows viable fetus. Treatment: Bed rest, folic acid, Anti-D if Rh-ve >12 weeks.
    • Inevitable: Heavy bleeding + clots, severe cramps, rupture of membranes. Cervix OPEN.
    • Incomplete: Partial expulsion. Cervix OPEN with tissue. Treatment: Ergometrine 0.5mg, fluid, surgical evacuation.
    • Complete: Empty uterus, Cervix CLOSED, pain/bleeding resolved. Check hCG to exclude ectopic.
    • Missed: Retention of dead embryo. Symptoms of pregnancy disappear. Cervix CLOSED. Diagnosed if: Crown-Rump Length (CRL) ≥7 mm with NO heart beat, OR Mean Sac Diameter >25 mm with NO fetal pole. Risk of Disseminated Intravascular Coagulation (DIC) causing hypofibrinogenemia if retained >4 weeks.
    • Septic: Mixed aerobes/anaerobes (E.coli, Clostridia). High fever, pelvic pain, offensive discharge. Associated with criminal abortion. Treat with IV cephalosporin + metronidazole BEFORE evacuation (delay 24h if bleeding not severe).
Miscarriage: Management & Medical Treatment
  • Expectant Management: First-line for 7-14 days if stable. Contraindicated in infection, high haemorrhage risk, or late 1st trimester. Good if retained product is <15mm.
  • Medical Treatment:
    • Prostaglandin analogue (Misoprostol): 400-800 mcg orally/vaginally. (Vaginal alone 50% success).
    • Progesterone antagonist (Mifepristone RU486): 400 mg orally. Combined success rate 90%. Complications: heavy bleeding, 10% need surgical evacuation.
  • Surgical Treatment (Curettage/Evacuation): For heavy bleeding or retained tissue >50mm. Vacuum aspiration is safer than sharp curettage. Complications: Perforation, Asherman syndrome, retained POC. Give Ergometrine 0.5mg to decrease blood loss.
  • Anti-D Immunoglobulin: Given to Rh-negative women.
💡 High-Yield Hints (L2)
  • Discriminatory Zone: An intrauterine sac MUST be seen on TVUS if hCG >1500 IU/L. If not, suspect ectopic.
  • Missed Abortion Strict Criteria: CRL ≥7 mm with NO heart beat OR Mean Sac Diameter >25 mm with NO fetal pole. Must confirm with 2nd US after 7 days.
  • DIC Risk: Missed abortion retained for >4 weeks risks DIC. Check serum fibrinogen before evacuation.
  • Cervix Status: Open in Inevitable & Incomplete. Closed in Threatened, Complete, & Missed.
  • Most Important Risk Factor for Miscarriage: Advanced maternal age (due to autosomal trisomy).

L3: (Recurrent Miscarriage II)(part I&II 8mcq)

Definition & Aetiology
  • Definition: 3 or more consecutive pregnancy losses before 24 weeks. Affects 1-2%. Idiopathic in 50%.
  • Causes:
    1. Immunological (15%): Antiphospholipid Syndrome (APS) (Anticardiolipin/Lupus anticoagulant cause thrombosis/infarcts), Systemic Lupus Erythematosus (SLE), Antithyroid antibodies.
    2. Genetic (2%): Parental balanced reciprocal translocation. Sperm DNA fragmentation (smoking, alcohol, obesity, advanced paternal age).
    3. Anatomic: Congenital (septate/bicornuate uterus), Acquired (Cervical weakness -> 2nd trimester loss, Asherman's, submucous fibroid). Adenomyosis may impede implantation.
    4. Endocrine: Polycystic Ovary Syndrome (PCOS) (luteal phase insufficiency/insulin resistance), poorly controlled Diabetes Mellitus, Thyroid disorders.
    5. Thrombophilias: Inherited (Factor V Leiden, Prothrombin gene mutation). Acquired (Antithrombin III, Protein S deficiency).
Investigations & Management
  • Investigations:
    • Anticardiolipin/Antiphospholipid screening: Needs two positive tests 12 weeks apart (IgG/IgM or titer >40g/L).
    • Thyroid Function Test (TFT) & Antithyroid antibodies.
    • Pelvic Imaging: Ultrasound / Hysterosalpingography for anatomy.
    • Parental Karyotyping & Cytogenetic analysis of conception products.
    • Thrombophilia screening (especially after a single 2nd-trimester loss).
  • Treatment:
    • Antiphospholipid Syndrome: Low dose aspirin + Low Molecular Weight Heparin (LMWH). Prednisolone/IVIG has limited benefit.
    • Anatomic: Cervical cerclage for weakness. Surgical correction of septa/fibroids.
    • Genetic: Gamete donation, In Vitro Fertilization (IVF) with Pre-implantation Genetic Diagnosis (PGD) for translocations.
    • Note on Aspirin: Empirical use for *all* recurrent miscarriages has no proven benefit.
💡 High-Yield Hints (L3)
  • APS Diagnosis: Requires TWO positive tests for Anticardiolipin/Lupus anticoagulant taken at least 12 weeks apart.
  • Aspirin Usage: Proven useful ONLY for Antiphospholipid Syndrome, NOT for unexplained recurrent miscarriage.
  • Genetic Testing: If an unbalanced translocation is suspected, test the products of conception and perform parental karyotyping.
  • Cervical Incompetence: Characteristically causes 2nd-trimester painless abortion or preterm labor.
  • PCOS Link: Causes miscarriage due to luteal phase insufficiency and insulin resistance.

L4: (Ectopic Pregnancy)(4mcq)

Epidemiology, Sites & Risk Factors
  • Definition: Implantation outside normal cavity. Most common cause of pregnancy-related death (2/3 due to substandard care). Incidence 1-2%.
  • Sites: 95-97% in Fallopian tube. 80% Ampullary. 2.5% Interstitial/Cornual (responsible for 20% of deaths due to massive rupture).
  • Risk Factors:
    • Maternal age (highest 35-44y).
    • Sexually Transmitted Diseases (STDs) / Pelvic Inflammatory Disease (PID): Chlamydia/Gonorrhea.
    • Contraception Failure: Tubal ligation, Intrauterine Contraceptive Device (IUCD), Progesterone only (increases ectopic ratio if pregnancy occurs).
    • Previous pelvic/tubal surgery.
    • In Vitro Fertilization (IVF) / Assisted reproduction.
    • Previous Ectopic: Recurrence risk increases to 10%.
    • Smoking: Alters tubal function. Dose-dependent.
    • In utero Diethylstilbestrol exposure.
    • Previous abdominal surgery (appendicectomy).
Clinical Presentation & Diagnosis
  • Presentation: Missed period, mild/old brown vaginal bleeding, pelvic pain (iliac fossa). Shoulder pain indicates diaphragmatic irritation from intraperitoneal blood.
    • Acute: Ruptured ectopic. Severe pain, shock (pallor, hypotension, tachycardia), rigid abdomen, fainting.
    • Subacute: Diagnostic challenge. Vitals normal. Most common presentation.
    • Decidual cast passage may be misdiagnosed as abortion. 10-20% have NO bleeding.
  • Diagnosis:
    • Transvaginal Ultrasound (TVUS): Single best tool. Inhomogeneous mass or extrauterine sac. 10-20% show pseudogestational sac in uterus. Fluid in Douglas pouch is non-specific.
    • Discriminatory hCG Zone: 1500-2000 IU/L. If hCG is above this and no intrauterine sac is seen, suspect ectopic.
    • Serial hCG: Slow rise (<35% in 48h) or plateau suggests ectopic. Normal doubles every 48h (rises >63%). Unhealthy IUP halves in 24-36h.
    • Progesterone: >25 ng/ml nearly excludes ectopic. <5 ng/ml suggests failing/ectopic.
    • Laparoscopy: Diagnostic & therapeutic if hCG > discriminatory zone with empty uterus.
Treatment (Medical & Surgical)
  • Medical Treatment (Methotrexate): Folic acid antagonist (inhibits DNA synthesis). Dose: 1mg/kg (min 50mg). Used in 25-30% of cases.
    • Contraindications: Liver/renal/haematological disease, active infection, immunodeficiency, breast feeding.
    • Criteria for Methotrexate: Haemodynamically stable, NO embryonic cardiac activity, ectopic mass <3.5 cm, NO haemoperitoneum, hCG <5000 IU/L.
    • Follow-up: Check hCG on Day 4 & Day 7. (Slight rise before fall is normal). If <25% fall by Day 7, give 2nd dose. Weekly testing until <25 IU/L (takes 4-5 weeks). 15% require surgical tx eventually.
    • Avoid pregnancy for 3 months (teratogenic), avoid sun/alcohol. Side effects: stomatitis, conjunctivitis.
  • Surgical Treatment: For unstable patients or sac >3.5 cm / +ve heartbeat. Operative laparoscopy preferred.
    • Salpingostomy / Salpingotomy: Conservative (leaves tube). 10-15% risk of persistent trophoblast (requires B-hCG follow up). Done if desire fertility & other tube is damaged.
    • Salpingectomy: Tube removal. Done if family complete, other tube healthy, recurrent ectopic in same tube, uncontrolled bleeding, or severely damaged tube.
  • Expectant: Mass <3cm, hCG <1000 IU/L, asymptomatic. Strict follow up until hCG <20 IU/L.
  • Anti-D: Given to Rh-ve non-sensitized women.
💡 High-Yield Hints (L4)
  • Most Fatal Ectopic Site: Interstitial/Cornual (2.5%) due to massive bleeding from rupture.
  • Pseudogestational Sac: Present in 10-20% of ectopics. Do not mistake it for a normal intrauterine pregnancy (check for Yolk Sac!).
  • Methotrexate Strict Rules: Sac <3.5 cm, NO heartbeat, hCG <5000, and hemodynamically stable. Check hCG on Days 4 & 7.
  • Methotrexate Side Effects: Teratogenic (avoid pregnancy 3 months), stomatitis, photosensitivity.
  • Persistent Trophoblast Risk: 10-15% risk if Salpingotomy (conservative surgery) is done. Always follow up with hCG.

L5: (Gestational Trophoblastic Diseases)(3mcq)

Classification & Epidemiology
  • Definition: Tumours of conceptus cells producing Human Chorionic Gonadotropin (hCG) (Beta subunit specific). Incidence 0.2-1.5/1000.
  • Classification (WHO):
    • Premalignant (GTD): Complete & Partial Hydatidiform Mole.
    • Malignant (GTN - Neoplasia): Invasive mole, Choriocarcinoma, Placental Site Trophoblastic Tumour (PSTT), Epithelioid Trophoblastic Tumour (ETT).
  • Risk Factors:
    • Maternal Age: Extremes (<16 and >45 years). >45y has 300-fold increased risk (mainly complete mole).
    • Ethnicity: Higher in Asian women.
    • Previous Mole: 10x risk (mostly complete mole).
    • Diet: Low carotene & animal fat.
Molar Pregnancies (Complete vs Partial)
  • Complete Hydatidiform Mole:
    • Genetics: Totally paternal (Diploid 46,XX most common, sperm fertilizes empty oocyte).
    • Pathology: Swollen chorionic villi (grape-like), diffuse atypia, NO fetus.
    • Symptoms: Amenorrhea, pain, bleeding. Exaggerated pregnancy (hyperemesis, early pre-eclampsia, hyperthyroidism). Uterus large for date & doughy.
    • Diagnosis: Snow storm appearance on US. Enormous hCG (>200,000 IU/L). Associated with bilateral Theca Lutein cysts.
    • Risk of malignancy: 20% persist to GTN.
  • Partial Hydatidiform Mole:
    • Genetics: Triploid (69 chromosomes) - 2 paternal sets, 1 maternal (dispermic fertilization of normal oocyte).
    • Pathology: Fetus present, focal hydropic villi. Often misdiagnosed as miscarriage.
    • Risk of malignancy: <0.5%.
Malignant GTN (Invasive, Choriocarcinoma, PSTT)
  • Invasive Mole: Invades myometrium. Can cause uterine perforation/haemorrhage. Usually follows complete mole.
  • Choriocarcinoma: Highly malignant. Follows any pregnancy type (term, abortion, mole). Widespread metastasis (Lungs, Brain, Liver, Vagina). Presents as bleeding or haemoptysis. Biopsy avoided due to severe haemorrhage risk.
  • Placental Site Trophoblastic Tumour (PSTT) & ETT: Rare, usually follows normal pregnancy (average 3.4 years later). Lower hCG. Less chemosensitive -> Hysterectomy is main treatment.
Treatment & Follow-up of GTD
  • Treatment of Mole: Suction curettage. Sharp curettage NOT recommended (perforation, Asherman risk, dissemination risk). Avoid medical termination / oxytocics before evacuation to prevent trophoblastic emboli.
  • Follow-up: Serial hCG every 2 weeks until normal, then monthly for 6-12 months. Avoid pregnancy for 12 months (or 6m post normal hCG).
  • Contraception: Intrauterine Device (IUD) avoided until hCG normal (risk of perf/bleeding). Combined Oral Contraceptive Pills (COCP) safely used in USA (UK advises avoiding until hCG normal).
  • Chemotherapy Indications for GTN: Raised hCG @ 6 months, plateau x3 samples, hCG >20,000 IU/L after 4 weeks, rising hCG x2 samples, lung/brain/liver/GIT metastasis.
  • FIGO Scoring: Evaluates Age, antecedent pregnancy (term is highest risk), interval months, hCG level, tumour size, site (Brain/liver highest risk), number of mets, previous chemo.
    • Low Risk (≤6): Single agent Methotrexate (IM) + Folinic acid (90% of cases).
    • High Risk (≥7): Combination EMA-CO (Etoposide, Methotrexate, Actinomycin, Cyclophosphamide, Vincristine).
  • Hysterectomy: Indicated for uncontrollable bleeding, chemo-resistant tumour, or PSTT/ETT. Does not eliminate need for hCG monitoring.
💡 High-Yield Hints (L5)
  • Complete Mole Genetics: Diploid (46, XX mostly), completely paternal origin (empty egg fertilized).
  • Partial Mole Genetics: Triploid (69, XXY/XXX), 2 sperms + 1 normal egg. Contains fetal tissue.
  • Biopsy in Choriocarcinoma: STRICTLY AVOIDED due to severe hemorrhage risk. Diagnose clinically + elevated hCG.
  • Oxytocics & Med Abortion in Mole: AVOIDED before evacuation to prevent trophoblastic emboli dissemination into maternal circulation.
  • PSTT Unique Tx: Hysterectomy is the primary treatment (unlike other GTNs) because it is less chemosensitive.

L6: (Benign Diseases of the Uterus)(4mcq)

Uterine Fibroids (Leiomyomas): Types & Degeneration
  • Definition: Most common benign solid tumour of smooth muscle. Oestrogen-dependent (enlarge in pregnancy, shrink post-menopause). Protectives: parity, smoking, COCP, Mirena, exercise.
  • Types:
    1. Submucous: Bulges into cavity. Causes most severe Heavy Menstrual Bleeding (HMB).
    2. Intramural: Central within myometrium.
    3. Subserous: Outer surface, may be pedunculated.
  • Degenerations:
    • Red Degeneration: Haemorrhage/necrosis due to blood supply impairment. Classically in 2nd trimester of pregnancy. Severe acute pain, localized tenderness, mild fever. Self-limiting (treat with analgesia).
    • Hyaline Degeneration: Asymptomatic softening/liquefaction.
    • Cystic Degeneration: Central necrosis following hyaline.
    • Calcification: End stage, common in postmenopausal women (visible on X-ray).
  • Leiomyosarcoma Risk: Exceedingly rare (0.5%). Occurs in 7th decade. Fibroids themselves are not considered direct precursors. Rapidly enlarging postmenopausal mass.
Fibroids: Symptoms, Diagnosis & Treatment
  • Symptoms: Mostly asymptomatic.
    • Heavy Menstrual Bleeding (Menorrhagia): Distorts cavity increasing surface area (Submucous).
    • Pressure: Bladder frequency, bowel constipation, pelvic dragging.
    • Pregnancy Complications: Subfertility (blocks ostia), malpresentation, Postpartum Haemorrhage (PPH) due to poor contraction. Red degeneration pain.
  • Diagnosis: Ultrasound (TVUS for submucous, Transabdominal for large/hydronephrosis check). Magnetic Resonance Imaging (MRI) maps exact location (pre-UAE).
  • Medical Treatment:
    • Non-Hormonal: Tranexamic acid & NSAIDs (less effective if >3cm or submucous).
    • Hormonal: Progesterone (high dose or Mirena LNG-IUS - caveat: cavity distortion makes insertion hard/expulsion risk). COCP does NOT cause enlargement.
    • GnRH agonists: Down-regulates pituitary. Shrinks fibroid by 40%, reduces vascularity. Used pre-operatively (allows Pfannenstiel incision, restores Hb). Long-term use contraindicated due to bone loss. Regrowth is rapid upon stopping. Masks surgical cleavage planes.
  • Surgical/Interventional Treatment:
    • Hysterectomy: Definitive cure if family complete.
    • Myomectomy: Preserves fertility. Risk of severe bleeding leading to emergency hysterectomy. Risk of disseminating sarcoma if power morcellator used.
    • Uterine Artery Embolization (UAE): Injects polyvinyl alcohol via femoral artery. Causes necrosis/shrinkage (50%). Complication: Post-embolization syndrome (7-10 days later: fever, pain, elevated WBC - cytokine release, not infection). Contraindicated in asymptomatic or active infection. Risk of premature ovarian failure.
💡 High-Yield Hints (L6)
  • Red Degeneration: Hallmark is acute severe localized pain in a fibroid during the 2nd trimester of pregnancy. Treat with simple analgesia.
  • Most Symptomatic Fibroid: Submucous fibroids cause the heaviest bleeding (HMB) and greatest fertility issues.
  • GnRH Agonist Role: Used PRE-OPERATIVELY to shrink mass (allows Pfannenstiel cut) and correct anemia. Never use long-term (Osteoporosis).
  • COCP and Fibroids: Contrary to old beliefs, COCP does NOT enlarge fibroids and actually protects against them.
  • Post-Embolization Syndrome: Occurs 7-10 days post-UAE (fever, pain, high WBCs). It is a cytokine response to necrosis, NOT an infection.

L7: (Endometrial Hyperplasia -pre-)(premalignant&malignant 2mcq)

Definition, Classification & Diagnosis
  • Definition: Irregular excessive proliferation of endometrial glands (gland to stroma ratio >2:1). Precursor to Endometrial Cancer.
  • Old Classification (1994):
    • Simple without atypia (Swiss cheese, 1% cancer risk).
    • Complex without atypia (Crowded back-to-back, 3% risk).
    • Simple atypical (8% risk).
    • Complex atypical (29% risk). Atypia = enlarged nuclei, prominent nucleoli, mitotic activity.
  • WHO 2014 Classification: 1. Hyperplasia without atypia. 2. Atypical Hyperplasia.
  • Symptoms: Abnormal Uterine Bleeding (AUB), Heavy Menstrual Bleeding (HMB), Intermenstrual, or Postmenopausal bleeding.
  • Diagnosis: Requires histological examination.
    • Transvaginal Ultrasound: Endometrial thickness <3-4 mm in postmenopausal women effectively excludes cancer. Overlaps with normal in premenopausal.
    • Pipelle (Outpatient sampling): Plastic suction tube. No anaesthesia, 10-15 mins. Limitations: inadequate sample, fails in cervical stenosis (28%), 0.9% cancer miss rate.
    • Dilatation & Curettage (D&C) or Hysteroscopy: Used if US shows polyps or if stenosis prevents Pipelle.
Treatment Guidelines
  • Hyperplasia Without Atypia:
    • Risk of cancer <5% in 20 yrs. May regress spontaneously. Stop HRT, lose weight.
    • Medical: Oral Progesterone (continuous Medroxyprogesterone 10-20mg or Norethisterone 10-15mg) OR Mirena LNG-IUS (Preferred, fewer side effects). Treat for 6 months minimum.
    • Follow-up: Needs 2 consecutive negative biopsies (6-month intervals). Keep Mirena for 5 years if fertility not desired.
    • Hysterectomy Indications: Progresses to atypia, fails to regress after 12 months, relapse after treatment, persistent bleeding, patient non-compliance.
  • Atypical Hyperplasia:
    • Coexists with cancer in 25-50% of cases.
    • Standard Treatment: Total Hysterectomy (Laparoscopic preferred: shorter stay, less pain).
    • Fertility Sparing (or unfit for surgery): Mirena or high dose oral progesterone. High relapse rate.
💡 High-Yield Hints (L7)
  • Atypical Hyperplasia Management: High risk of co-existing cancer (25-50%). Definitive treatment is ALWAYS Hysterectomy unless fertility is strongly desired.
  • Postmenopausal US Cutoff: Endometrial thickness < 3-4 mm effectively excludes cancer.
  • Best Medical Tx for Hyperplasia w/o Atypia: LNG-IUS (Mirena) is preferred over oral due to higher efficacy and fewer side effects. Keep for 5 years.
  • Pipelle Limitation: Fails in 28% of cases due to cervical stenosis. If it fails, proceed to Hysteroscopy/D&C.

L8: (Malignant Uterine Disease)(premalignant&malignant 2mcq)

Aetiology, Risk Factors & Protection
  • Most common gynecological malignancy in western countries.
  • Risk Factors:
    • Obesity: Adipose tissue converts androgens to oestrogen. Huge link to epidemic.
    • Nulliparity.
    • Endometrial Hyperplasia: Atypical hyperplasia has 46% risk of frank malignancy on sampling (don't delay surgery!).
    • Early menarche & late menopause (>52 years).
    • Polycystic Ovary Syndrome (PCOS): Amenorrhoea leads to unopposed oestrogen. Must induce artificial withdrawal bleeds.
    • Unopposed Oestrogen therapy.
    • Tamoxifen: Used in breast cancer; increases incidence of rare tumours like carcinosarcoma.
    • Lynch Syndrome (Type 2 familial cancer): Genetic predisposition to colorectal/ovarian/endometrial cancers.
  • Protective Factors:
    • Combined Oral Contraceptives (COCP) & Progesterone only pills: Decrease incidence by 50%.
    • Intrauterine Devices (Copper IUD, LNG-IUS).
    • Pregnancy, healthy weight, exercise.
    • Smoking: Has anti-oestrogenic effect (decreases incidence).
Classification, Diagnosis & Staging
  • Type 1 vs Type 2: Type 1 is estrogen-dependent, low grade (Endometrioid), common, good prognosis. Type 2 is non-estrogen dependent, poor prognosis (Serous/Clear cell).
  • Molecular Classification:
    1. POLE-mutant (Excellent outcome, low recurrence).
    2. MMR-deficient (Intermediate prognosis, 10% link to Lynch syndrome).
    3. No specific profile (Endometrioid, intermediate to excellent).
  • Clinical Features:
    • Postmenopausal Bleeding (PMB): 90% presentation. (10% of all PMB is cancer).
    • Pre-menopausal: Irregular bleeding / blood-stained discharge.
    • Pelvic pain, dyspareunia. Advanced: bowel/urinary dysfunction.
  • Diagnosis:
    • US >4mm in PMB requires biopsy. Biopsy via Pipelle, D&C, or Hysteroscopy.
  • Staging & Evaluation:
    • Magnetic Resonance Imaging (MRI): Method of choice for clinical staging (assesses myometrial/cervical invasion, pelvic/para-aortic lymph nodes).
    • CT Scan: For chest/abdomen/pelvis in high-grade tumours to exclude distant metastasis (lungs, vagina).
    • Staging is Surgico-Pathological. Key factors: Depth of myometrial invasion, Grade (1, 2, 3), Lymphovascular space invasion.
    • Surgery: Type 2 or high-grade Type 1 requires omental biopsy & peritoneal washing.
    • Radiotherapy +/- chemo used post-op depending on staging.
💡 High-Yield Hints (L8)
  • Most Common Symptom: Postmenopausal bleeding (PMB) is seen in 90% of cases. Always investigate PMB with US/Biopsy.
  • Tamoxifen Effect: Treats breast cancer but ironically INCREASES risk of endometrial cancer (acts as estrogen agonist in the uterus).
  • Smoking Paradox: Smoking actually DECREASES the risk of endometrial cancer due to its anti-estrogenic effect.
  • PCOS Danger: Chronic anovulation leads to continuous unopposed estrogen, highly increasing cancer risk. Ensure withdrawal bleeds.
  • MRI Role: The method of choice for PRE-OPERATIVE STAGING (checks myometrial/cervical depth).

L9: (Minimal Access Surgery)(2mcq)

Laparoscopy: Advantages, Contraindications & Entry
  • Advantages vs Open: Shorter stay, rapid return to activity, less postoperative adhesions (crucial for fertility), less wound infection.
  • When Open is needed: Very large masses, advanced malignancy, severe adhesions, emergency rapid access.
  • Pre-operative evaluation: Check for adhesions (PID/Endometriosis history), scars, hernias, mesh.
  • Entry Techniques:
    • Palmer's Point: 3 cm below left costal margin in midclavicular line. Used if periumbilical adhesions, huge mass, or obesity exist. Stomach must be empty. Contraindications: Splenomegaly, previous gastric surgery, portal hypertension.
    • Closed Technique (Veress Needle): Quick access. Disadvantage: Higher risk of vascular injury compared to open technique. Small 2mm needle with spring-loaded obturator. Sensation of 2 'pops' (fascia, peritoneum). Entry angle: 45 degrees in thin patients (up to 60 in obese) because Aorta is <4cm from umbilicus.
  • Complications: Port-site hernia (Must suture fascia if port is >10mm), Ureter injuries (most common in Laparoscopic hysterectomy).
Hysteroscopy
  • Camera-equipped tube (rigid or flexible) into uterus via cervix.
  • Diagnostic (outpatient, no anaesthesia) vs Operative (paracervical block or GA).
  • Distension Media: Required pressure 70-80 mmHg.
    • Electrolyte-containing: Normal saline / Ringer lactate (Diagnostic).
    • Electrolyte-poor: Glycine 1.5%, Dextrose 5%, Mannitol (Operative).
  • Indications: AUB, polyps, endocervical lesions, submucous fibroid, Asherman's, retained IUCD/POC, mullerian anomalies, tubal ostia evaluation.
  • Complications:
    • Uterine Perforation: Bowel damage, intraperitoneal haemorrhage.
    • Fluid Absorption Syndrome: Risk increases if pressure > Mean Arterial Pressure (100 mmHg). Causes hyponatremia & hypo-osmolarity -> Nausea, vomiting, seizures, coma, death.
💡 High-Yield Hints (L9)
  • Palmer's Point Location: 3 cm below left costal margin, midclavicular line. Used to avoid umbilical adhesions.
  • Palmer's Contraindications: Splenomegaly, gastric surgery, portal hypertension. Stomach MUST be empty.
  • Veress Needle Risk: "Closed technique" has a higher risk of vascular injury (aorta/vena cava) than open entry.
  • Fluid Absorption Syndrome: Occurs during operative hysteroscopy. Causes dangerous Hyponatremia. Keep pressure below 100 mmHg!
  • Port Hernia Prevention: Always suture the fascial defect if the trocar port is > 10mm.

L10: (Ovarian Disease Part 1)(part I&II 5mcq)

Anatomy & Differential Diagnosis
  • Anatomy: Resting ovary is 3 x 2 x 1 cm. Shrinks after menopause. Surface covered by flat single layer epithelium. Contains follicles (oocyte, granulosa layer, theca cells).
  • Differential Diagnosis of Pelvic Mass:
    • Gynaecological: Pregnancy, ectopic, ovarian cyst (benign/malignant), tubo-ovarian abscess, hydrosalpinx, pyosalpinx, fibroid.
    • GIT: Appendicular/diverticular abscess, obstruction, malignancy.
    • Urological: Pelvic kidney, hydronephrosis, bladder cancer.
    • Other: Lymphoma, psoas abscess, peritoneal cyst.
Functional & Epithelial Cysts
  • Functional Cysts (Physiological): Asymptomatic, common in young. Incidence decreased by COCP.
    • Follicular Cyst: Commonest. Non-rupture of dominant follicle. >3 cm, rarely >10 cm. Lined by granulosa cells. Unilocular. Treatment: Observation (resolves in 8-16w). Lap. cystectomy if symptomatic >8-16 weeks.
    • Corpus Luteum Cyst: Occurs after ovulation. Reaches up to 5cm, regresses.
    • Theca Luteal Cysts: Associated with pregnancy/GTD/hCG levels.
  • Epithelial Tumours: Commonest in old women (60-65% of all tumours).
    • Serous Tumours: Lined by ciliated cells (tubal-like). Often bilateral. Psammoma bodies (calcospheroles) present in malignant type.
    • Mucinous Tumours: Benign (Cystadenoma) is multilocular, very large (up to 14 kg). Fluid is thick, gel-like. Lined by endocervical-like cells. Complication: Pseudomyxoma Peritonei (borderline tumour seedlings secrete mucin, mats bowel causing obstruction).
    • Endometrioid Tumours: Similar to endometrium, hard to differentiate from endometriosis.
    • Clear Cell & Brenner Tumours (Transitional cell, mostly benign).
Germ Cell Tumours
  • 30% of ovarian tumours. Most common in young women (early 20s).
  • Tumour Markers:
    • Yolk Sac Tumour (Endodermal sinus): High Alpha-Fetoprotein (AFP). Highly malignant.
    • Embryonal Carcinoma: Rare, secretes B-hCG and AFP.
    • Choriocarcinoma (Non-gestational): Secretes B-hCG.
  • Mature Cystic Teratoma (Dermoid Cyst):
    • Most common germ cell tumour. Ages 18-30. Bilateral in 15%.
    • Unilocular, <15cm. Ectodermal predominance (hair, teeth, bone, sebaceous). Endodermal (thyroid). Visible on X-Ray due to teeth/bone.
    • Complication: 15% present acutely due to Torsion (most common ovarian tumour to undergo torsion). Cuts blood supply, severe acute pain, nausea.
  • Dysgerminoma: Malignant. Occurs in 5-10% of phenotypic females with abnormal gonads (androgen insensitivity).
💡 High-Yield Hints (L10)
  • Dermoid Cyst Complication: It is the MOST common ovarian tumour to undergo TORSION. High fat content makes it float/twist.
  • Pseudomyxoma Peritonei: Result of borderline mucinous cystadenoma seeding. Secretes mucin that mats the bowel -> Obstruction.
  • Psammoma Bodies: Calcospheroles classically found in Serous Ovarian Carcinoma.
  • Tumour Markers to Memorize: Yolk Sac = AFP. Choriocarcinoma = hCG. Dysgerminoma = LDH/hCG.
  • Follicular Cysts: Extremely common, physiologic. Management is OBSERVATION first (resolves usually in 8-16 weeks).

L11: (Ovarian Diseases Part 2)(part I&II 5mcq)

Sex Cord Stromal Tumours & Clinical Features of EOC
  • Sex Cord Stromal Tumours:
    • Fibroma: Most common sex cord tumour. Solid, hard, white, mobile. Occurs around 50 years. Presents with torsion due to heaviness. Associated with Meigs Syndrome (Ovarian Fibroma + Ascites + Pleural Effusion). Resolves after removal.
    • Thecoma: Benign, produce oestrogen -> PMB or precocious puberty. May cause endometrial hyperplasia.
    • Granulosa Cell Tumours: Low malignant potential, secrete oestrogen/inhibin. Treated by unilateral salpingo-oophorectomy in young. Late recurrences happen.
  • Epithelial Ovarian Cancer (EOC) Presentation:
    • Vague pressure symptoms leading to late presentation. 66% present at Stage 3 or more.
    • Symptoms: Abdominal swelling/bloating, early satiety, urinary urgency, unexplained weight loss. Abnormal bleeding is less common. Mimics IBS.
    • History: Nulliparity, HRT, Family history (BRCA). Endometriosis & PID increase cancer risk (chronic inflammation). Tubal ligation & hysterectomy decrease risk.
    • Examination: Fixed hard mass, clinical ascites, pleural effusion, inguinal nodes.
Diagnosis & Risk of Malignancy Index (RMI)
  • Investigations: Transvaginal Ultrasound (TVUS). Malignancy signs: Multilocular, thick wall, solid areas, bilateral, ascites, metastasis.
  • Tumour Markers: CA-125 (elevated in 80% of serous EOC), CA19-9 (mucinous EOC), CEA (GI primary rule out). CA-125 can be falsely elevated in Endometriosis/PID (levels <200). Rapid rising is malignant.
  • Risk of Malignancy Index (RMI): Product of CA-125 level × Ultrasound Score (0, 1, or 3) × Menopausal State (1=Pre, 3=Post).
  • RMI Ultrasound Points (1 point each): Multilocular, Solid areas, Bilateral, Metastasis, Ascites.
  • Management by RMI:
    • Low Risk (RMI < 25): <3% cancer risk. Cyst <5cm -> Conservative (US + CA-125 every 4m).
    • Moderate Risk (RMI 25-250): 20% risk. Laparoscopic oophorectomy.
    • High Risk (RMI > 250): >75% risk. Cancer center, full staging laparotomy.
EOC Staging & Treatment
  • Staging (FIGO):
    • Stage 1: Limited to ovaries. (1a: one ovary, capsule intact. 1c: ruptured/ascites).
    • Stage 2: Pelvic extension.
    • Stage 3a/3b/3c: Abdominal spread. 3b: Tumour implant on abdominal peritoneum ≤2cm, negative nodes. 3c: Abdominal implants >2cm OR positive retroperitoneal/inguinal nodes.
    • Stage 4: Distant metastasis (Pleural effusion, liver).
  • Treatment:
    • Young patient (Fertility sparing): Complete staging, leave uterus/contralateral ovary, await histology. 7% recurrence.
    • Advanced Disease: Cytoreductive Surgery (TAH/BSO, complete omentectomy, resection of metastasis, appendicectomy). Objective is tumour cytoreduction to improve chemotherapy response.
💡 High-Yield Hints (L11)
  • Meigs Syndrome: Triad of Ovarian Fibroma + Ascites + Pleural effusion. Cures instantly upon tumor removal.
  • Late Presentation of EOC: 66% present at Stage 3 or later because early symptoms are vague (mimics IBS: bloating, early satiety).
  • RMI Components (Crucial): CA-125 value, Menopausal status (1 or 3), and US score (0, 1, or 3 based on 5 features).
  • CA-125 False Positives: Elevated in Endometriosis, PID, Fibroids, and menstruation. Values >200 are highly suspicious for malignancy.
  • Cytoreductive Surgery (Debulking): The goal in advanced EOC is to physically remove as much tumor mass as possible to make post-op chemo work better.

📊 Ultimate Comparisons (10 Tables)

1. Complete vs. Partial Hydatidiform Mole
Feature Complete Mole Partial Mole
Karyotype 46, XX (Diplody) - 100% Paternal origin 69, XXY/XXX (Triploidy) - 2 Paternal + 1 Maternal
Fetal Tissue Absent Present
Pathology Diffuse hydropic swelling, diffuse trophoblast hyperplasia Focal hydropic swelling, focal hyperplasia
Ultrasound Snow-storm appearance Often misdiagnosed as missed abortion
hCG Level Extremely high (>200,000 IU/L) Mildly to moderately elevated
Malignancy Risk 20% (High risk of GTN) <0.5% (Low risk)
2. Types of Miscarriage (Expanded)
Type Vaginal Bleeding Pain/Cramps Cervical Os Ultrasound Findings Treatment Important Notes
Threatened Mild None / Mild Closed Live intrauterine fetus Supportive, Bed rest, Folic acid, Anti-D if >12w (Rh-ve). Most common. Reassurance is key. Repeat US after 7 days.
Inevitable Heavy + Clots Severe Open Impending expulsion, Ruptured membranes Expectant, Medical, or Surgical. Ergometrine 0.5mg if heavy bleeding. Will definitely progress to either complete or incomplete abortion.
Incomplete Heavy Severe Open Retained products of conception (POC) IV fluids, Ergometrine 0.5mg, Surgical evacuation (Vacuum aspiration). May cause Cervical Shock (vagal response) due to tissue in cervix.
Complete Resolved/Trace Resolved Closed Empty uterus Supportive. Check serum hCG. Must check hCG to exclude ectopic if previous US didn't confirm IUP.
Missed None / Light brown None Closed Dead fetus / Empty sac >25mm D&C OR Medical (Misoprostol 400-800mcg + Mifepristone 400mg). Risk of DIC (hypofibrinogenemia) if retained >4 weeks! Check fibrinogen.
Septic Offensive discharge Severe, Fever, Shock Open/Closed Retained POC / Pus IV Cephalosporin + Metronidazole. Delay evacuation 24h if bleeding not severe. Mixed aerobes/anaerobes. Associated with criminal abortion. High mortality.
3. Endometriosis vs. Adenomyosis
Feature Endometriosis Adenomyosis
Definition Endometrial glands/stroma OUTSIDE the uterus Endometrial glands/stroma INSIDE the myometrium
Typical Patient Young, nulliparous (often teenagers onset) Older (Late 30s-40s), Parous
Key Symptoms Dysmenorrhea, deep dyspareunia, subfertility Heavy menstrual bleeding (HMB), dysmenorrhea
Uterine Exam Fixed, retroverted uterus, Pouch of Douglas nodules Bulky, tender uterus
Best Diagnosis Laparoscopy (Gold standard) MRI (Investigation of choice)
Surgical Cure Excision (Myomectomy/Ablation) Hysterectomy (Definitive)
4. Ectopic Pregnancy: Medical vs. Surgical Management
Parameter Medical (Methotrexate) Surgical (Laparoscopy)
Indications Stable, hCG <5000, Sac <3.5cm, No fetal heart Unstable (Ruptured), high hCG, large mass, +ve heart
Contraindications Liver/Renal disease, Immunodeficiency, Breastfeeding Unfit for anaesthesia (rare, life-saving)
Advantages Avoids surgery/anesthesia, preserves tube fully Immediate resolution, controls active bleeding
Disadvantages Takes weeks (4-5), teratogenic (delay preg 3 mo), 15% fail Surgical risks, 10-15% persistent trophoblast (Salpingotomy)
5. Ovarian Tumours: Epithelial vs. Germ Cell vs. Sex Cord
Category Epithelial (60-65%) Germ Cell (30%) Sex Cord Stromal
Age Group Old women (Postmenopausal) Young women (Early 20s) All ages (Fibroma in 50s)
Common Benign Serous / Mucinous Cystadenoma Dermoid Cyst (Mature Teratoma) Fibroma
Common Malignant Serous Carcinoma (most common) Dysgerminoma, Yolk Sac Granulosa Cell Tumour
Markers / Signs CA-125 (Serous), CEA (Mucinous) AFP (Yolk), hCG (Chorio) Oestrogen (Thecoma), Meigs
6. Endometrial Hyperplasia: Without Atypia vs. Atypical
Feature Without Atypia Atypical Hyperplasia
Cancer Risk < 5% 25 - 50%
Cellular Changes Increased gland:stroma ratio only Nuclear enlargement, prominent nucleoli
Primary Treatment Mirena LNG-IUS or Oral Progesterone Total Hysterectomy
Follow-up Biopsy every 6 months until 2 negatives Post-op follow up (or strict monitoring if refusing surgery)
7. Risk of Malignancy Index (RMI) for Ovarian Cysts
RMI Group Score Range Risk of Cancer Management Plan
Low Risk RMI < 25 < 3% Conservative (US + CA-125 every 4 months)
Moderate Risk RMI 25 - 250 20% Laparoscopic oophorectomy
High Risk RMI > 250 > 75% Cancer center referral + Full Staging Laparotomy
8. Laparoscopic Entry: Palmer's Point vs. Closed (Veress) Technique
Method Palmer's Point Closed (Veress) Technique
Site 3 cm below left costal margin (Midclavicular) Umbilicus (Horizontal/Vertical incision)
Main Indications Periumbilical adhesions, huge pelvic mass, obesity Standard quick entry in uncomplicated cases
Key Contraindications Splenomegaly, gastric surgery, portal hypertension Previous severe umbilical adhesions/hernias
Complication Risk Gastric/Splenic injury (must empty stomach) Higher risk of major vascular injury (Aorta/IVC)
9. Uterine Fibroids: Medical vs. Surgical vs. UAE
Treatment Category Options Available Fertility Preservation Key Pros & Cons
Medical (Hormonal & Non-Hormonal) NSAIDs, Tranexamic Acid, COCP, Mirena LNG-IUS, GnRH Agonists Yes (but some act as contraceptives during use) Pro: Non-invasive, GnRH shrinks fibroids pre-op (40%).
Con: Does NOT eradicate. GnRH limits >6 months due to bone loss.
Surgical Myomectomy (Lap/Open), Hysterectomy Yes (Myomectomy), No (Hysterectomy) Pro: Hysterectomy is definitive cure.
Con: Myomectomy risks severe bleeding leading to emergency hysterectomy. Adhesions risk.
Uterine Artery Embolization (UAE) Polyvinyl alcohol injection via femoral artery Questionable (Risk of Premature Ovarian Failure) Pro: Minimally invasive, shrinks fibroid 50%.
Con: Post-Embolization Syndrome (Fever/Pain at 7-10 days). Unsuitable if active infection.
10. Endometrial Cancer: Type 1 vs. Type 2
Feature Type 1 (Endometrioid) Type 2 (Serous / Clear Cell)
Estrogen Dependency Yes (Estrogen-related) No (Non-estrogen dependent)
Precursor Lesion Endometrial Hyperplasia Endometrial Atrophy
Tumor Grade & Histology Low Grade (Endometrioid) High Grade (Serous, Clear Cell, Carcinosarcoma)
Typical Patient Profile Perimenopausal / Early Postmenopausal, Obese Older Postmenopausal women, Thin
Prognosis Good (Favorable outcome) Poor (Highly aggressive)